- Advanced search
- Immuno Portal
- Malaria Portal
Synonyms: Invicorp® (aviptadil + phentolamine) | Vasoactive intestinal octacosapeptide
aviptadil is an approved drug (Sweden (2015))
Compound class: Peptide or derivative
Comment: Aviptadil is a vasoactive intestinal peptide analogue, VPAC1 receptor agonist.
|No information available.|
|Summary of Clinical Use|
|Aviptadil (by inhalation) has been granted EMA orphan designation for the treatment of sarcoidosis (2007) and acute lung injury (2006). In these indications its primary mechanism of action is suggested to be immunomodulation, decreasing the inflammatory function of lymphocytes and monocytes in the lung.
Invicorp (aviptadil + phentolamine) is authorised in some jurisdictions (e.g. Denmark, Finland, Norway, Sweden) as an injectable therapeutic for neurogenic, vasculogenic, psychogenic, or mixed aetiology erectile dysfunction, particularly where oral therapies (e.g. oral phosphodiesterase type-5 inhibitors) are ineffective.
SARS-CoV-2 and COVID-19: In severe cases COVID-19 can lead to acute respiratory distress syndrome (ARDS). Preclinical and clinical experience shows that aviptadil restores function in pulmonary hypertension, ARDS, and acute lung injury (ALI), reduces IL-6 and TNFα production, and protects against pulmonary edema. This combination of benefits has led to aviptadil being investigated as a treatment option for ARDS in COVID-19 patients.
|Clinical Trial ID||Title||Type||Source||Comment||References|
|NCT04311697||Intravenous Aviptadil for COVID-19 Associated Acute Respiratory Distress||Phase 2 Interventional||NeuroRx, Inc.|
|NCT04360096||Inhaled Aviptadil for the Treatment of Non-Acute Lung Injury in COVID-19||Phase 2/Phase 3 Interventional||NeuroRx, Inc.|